Cargando…
TAK1-inhibitors did not reduce disease burden in a Vκ*MYC model of multiple myeloma
OBJECTIVE: Multiple myeloma is a haematological malignancy characterized by proliferation of monoclonal plasma cells in the bone marrow. Development of resistance and minimal residual disease remain challenging in the treatment of multiple myeloma. Transforming growth factor-β activated kinase 1 (TA...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701378/ https://www.ncbi.nlm.nih.gov/pubmed/36435864 http://dx.doi.org/10.1186/s13104-022-06237-3 |
_version_ | 1784839517702717440 |
---|---|
author | Håland, Erling Moen, Ingrid Nyhus Vandsemb, Esten N. Starheim, Kristian K. |
author_facet | Håland, Erling Moen, Ingrid Nyhus Vandsemb, Esten N. Starheim, Kristian K. |
author_sort | Håland, Erling |
collection | PubMed |
description | OBJECTIVE: Multiple myeloma is a haematological malignancy characterized by proliferation of monoclonal plasma cells in the bone marrow. Development of resistance and minimal residual disease remain challenging in the treatment of multiple myeloma. Transforming growth factor-β activated kinase 1 (TAK1) has recently gained attention as a potential drug target in multiple myeloma. This study aimed at determining the in vivo effects of TAK1-inhibitors in a Vκ*MYC multiple myeloma mouse model. RESULTS: We treated mice carrying Vκ*MYC multiple myeloma cells with the TAK1-inhibitors 5Z-7-oxozeaenol and NG25. There were tendencies towards increased survival for both inhibitors, but only NG25 prolonged survival significantly. However, this effect was limited, and no differences in disease burden were observed for any of the treatments. In conclusion, although TAK1-inhibitors might prolong survival somewhat, they do not prevent disease in the Vκ*MYC mouse model of multiple myeloma. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13104-022-06237-3. |
format | Online Article Text |
id | pubmed-9701378 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-97013782022-11-28 TAK1-inhibitors did not reduce disease burden in a Vκ*MYC model of multiple myeloma Håland, Erling Moen, Ingrid Nyhus Vandsemb, Esten N. Starheim, Kristian K. BMC Res Notes Research Note OBJECTIVE: Multiple myeloma is a haematological malignancy characterized by proliferation of monoclonal plasma cells in the bone marrow. Development of resistance and minimal residual disease remain challenging in the treatment of multiple myeloma. Transforming growth factor-β activated kinase 1 (TAK1) has recently gained attention as a potential drug target in multiple myeloma. This study aimed at determining the in vivo effects of TAK1-inhibitors in a Vκ*MYC multiple myeloma mouse model. RESULTS: We treated mice carrying Vκ*MYC multiple myeloma cells with the TAK1-inhibitors 5Z-7-oxozeaenol and NG25. There were tendencies towards increased survival for both inhibitors, but only NG25 prolonged survival significantly. However, this effect was limited, and no differences in disease burden were observed for any of the treatments. In conclusion, although TAK1-inhibitors might prolong survival somewhat, they do not prevent disease in the Vκ*MYC mouse model of multiple myeloma. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13104-022-06237-3. BioMed Central 2022-11-26 /pmc/articles/PMC9701378/ /pubmed/36435864 http://dx.doi.org/10.1186/s13104-022-06237-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Note Håland, Erling Moen, Ingrid Nyhus Vandsemb, Esten N. Starheim, Kristian K. TAK1-inhibitors did not reduce disease burden in a Vκ*MYC model of multiple myeloma |
title | TAK1-inhibitors did not reduce disease burden in a Vκ*MYC model of multiple myeloma |
title_full | TAK1-inhibitors did not reduce disease burden in a Vκ*MYC model of multiple myeloma |
title_fullStr | TAK1-inhibitors did not reduce disease burden in a Vκ*MYC model of multiple myeloma |
title_full_unstemmed | TAK1-inhibitors did not reduce disease burden in a Vκ*MYC model of multiple myeloma |
title_short | TAK1-inhibitors did not reduce disease burden in a Vκ*MYC model of multiple myeloma |
title_sort | tak1-inhibitors did not reduce disease burden in a vκ*myc model of multiple myeloma |
topic | Research Note |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701378/ https://www.ncbi.nlm.nih.gov/pubmed/36435864 http://dx.doi.org/10.1186/s13104-022-06237-3 |
work_keys_str_mv | AT halanderling tak1inhibitorsdidnotreducediseaseburdeninavkmycmodelofmultiplemyeloma AT moeningridnyhus tak1inhibitorsdidnotreducediseaseburdeninavkmycmodelofmultiplemyeloma AT vandsembestenn tak1inhibitorsdidnotreducediseaseburdeninavkmycmodelofmultiplemyeloma AT starheimkristiank tak1inhibitorsdidnotreducediseaseburdeninavkmycmodelofmultiplemyeloma |